Skip to main content

2 January 2014

Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.

The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.

PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.

The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.

General media enquiries

Contact our global media and communications team at:

Tom Steiner

Tom Steiner

Vice president, Head of Communications & Government Affairs

+44 (0) 20 7004 1600

Email Arrow right icon
Alice Knight

Alice Knight

Corporate Communications Executive

+44 (0) 7748945205

Email Arrow right icon

Please note – the press team can only answer enquiries from accredited members of the press.

Related articles

Market Ceremony 3

Smiths honoured at the London Stock Exchange

Read our latest company news as Smiths is honoured at the London Stock Exchange.

Find out more Call to action arrow icon
Laurence Picture Morgan 1

Smiths appoints new independent Non-executive Director

Read our latest company news as the Board of Smiths is pleased to announce the appointment of Laurence Mulliez as an independent Non-executive Director, with effect from 1 September 2026.

Find out more Call to action arrow icon
Earth View

Smiths Group plc – Q3 trading update

Find out more Call to action arrow icon
Sign up for updates Call to action arrow icon